Business Context and Reporting Period
This Form 8-K is a Current Report filed by Predictive Oncology Inc. (not Axe Compute Inc. as indicated in metadata) on September 9, 2025. The registrant is incorporated in Delaware and trades on the NASDAQ Capital Market under the symbol POAI. The report addresses Item 5.02 regarding the appointment of certain officers and compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive compensation grants.
Material Changes and Executive Compensation
On September 9, 2025, the Board of Directors approved the grant of Restricted Stock Units (RSUs) under the Company's 2024 Equity Incentive Plan. The specific grants are as follows:
- Raymond F. Vennare (Chief Executive Officer): 124,959 RSUs.
- Josh Blacher (Interim Chief Financial Officer): 97,000 RSUs.
Each RSU represents the right to receive one share of common stock upon vesting. The awards vest in full on October 31, 2025, contingent upon continued service through that date.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. The only material item disclosed is the specific terms of the RSU grants, which are qualified by reference to the full Restricted Stock Unit Award Agreement filed as Exhibit 10.1.
Investor Verification Checklist
- Verify the total number of shares authorized under the 2024 Equity Incentive Plan to assess dilution impact.
- Review Exhibit 10.1 for specific performance conditions or clawback provisions not detailed in the summary.
- Confirm the current market price of POAI stock to estimate the fair value of the 221,959 total RSUs granted.
- Note the discrepancy between the metadata company name ("Axe Compute Inc.") and the actual registrant ("Predictive Oncology Inc.").